How Administration of Bispecific T-Cell Engagers Has Evolved

A clinical pharmacist explains how their practice has evolved related to the administration of bispecific T-cell engagers.

Video Player is loading.

Play Video

Play

Mute

Current Time 

/

Duration 

Loaded: 0%

Stream Type LIVE

Seek to live, currently behind liveLIVE

Remaining Time -

 

1x

Playback Rate

Chapters

• Chapters

Descriptions

• descriptions off, selected

Captions

• captions and subtitles off, selected

Audio Track

Fullscreen

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

Text

ColorWhiteBlackRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-Transparent

Background

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentTransparent

Window

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyTransparentSemi-TransparentOpaque

Font Size

50%75%100%125%150%175%200%300%400%

Text Edge Style

NoneRaisedDepressedUniformDropshadow

Font Family

Proportional Sans-SerifMonospace Sans-SerifProportional SerifMonospace SerifCasualScriptSmall Caps

Reset restore all settings to the default valuesDone

Close Modal Dialog

End of dialog window.

EP: 1.Introduction to Bispecific Antibodies: Operationalizing Administration and Follow-Up

EP: 2.Overview of Bispecific Engagers Administration Program

EP: 3.Program Development and SOPs for Bispecific Engagers

EP: 4.Treating Patients With Bispecific Engagers

EP: 5.The Grading and Management of Early and Late Adverse Events

Now Viewing

EP: 6.How Administration of Bispecific T-Cell Engagers Has Evolved

EP: 7.Closing Remarks on Bispecific Antibodies

Recent Videos

Treatment Implementation and Long-Term Considerations in BPDCN

Academic Perspectives on the Evolving Treatment Landscape in MPNs

Adverse Events Monitoring and Management in BPDCN Treatment

Academic Perspectives on Treatment Decisions for BPDCN

Quality of Life in MPNs: Patient-Centered Factors That Shape Treatment Approaches

Advances in MPN Management: Insights From MANIFEST-2 and Beyond

Ongoing studies of Ra-223–based combinations

Academic Perspectives on Systemic Therapy for Advanced uHCC

Ongoing studies of Ra- 223–based combinations

Protecting bone health for patients receiving Ra-223 + ARPI combination